Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=501	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=502	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=503
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13356, http://www.uniprot.org/uniprot/Q9GZU1	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13357, http://www.uniprot.org/uniprot/Q8IZK6	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:13358, http://www.uniprot.org/uniprot/Q8TDD5
Endogenous activators	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794 (Also activates other TRPMLs) (pEC50 7.3) [http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus]	–	–
Activators	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386 (pEC50 7.3) [‐140mV] [http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9783 (pEC50 7) [‐200mV] [http://www.ncbi.nlm.nih.gov/pubmed/25119295?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6389 (pEC50 6.3) [‐200mV] [http://www.ncbi.nlm.nih.gov/pubmed/25119295?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6387 (pEC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus] TRPML1Va: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386 Concentration range: 1×10−5M [‐140mV] [http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794 Concentration range: 1×10−6M [‐140mV] [http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus] TRPML2Va: Constitutively active, current potentiated by extracellular acidification (equivalent to intralysosomal acidification)	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6386 Concentration range: 1×10−5M [‐140mV] [http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2794 Concentration range: 1×10−6M [‐140mV] [http://www.ncbi.nlm.nih.gov/pubmed/20802798?dopt=AbstractPlus]
Selective activators Channel blockers	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2426 (Antagonist) (pIC50 4.7) [‐80mV] [http://www.ncbi.nlm.nih.gov/pubmed/18162548?dopt=AbstractPlus] – Mouse
	–	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10301 (Agonist) (pEC50 5.9) [‐100mV] [http://www.ncbi.nlm.nih.gov/pubmed/30479274?dopt=AbstractPlus]
Functional Characteristics	TRPML1Va: γ = 40 pS and 76‐86 pS at very negative holding potentials with Fe2+ and monovalent cations as charge carriers, respectively; conducts Na+≅ K+>Cs+ and divalent cations (Ba2+>Mn2+>Fe2+>Ca2+> Mg2+ > Ni2+ > Co2+ > Cd2+ > Zn2+≫Cu2+); monovalent cation flux suppressed by divalent cations (e.g. Ca2+, Fe2+); inwardly rectifying	Conducts Na+; monovalent cation flux suppressed by divalent cations; inwardly rectifying	TRPML3Va: γ = 49 pS at very negative holding potentials with monovalent cations as charge carrier; conducts Na+ > K+ > Cs+ with maintained current in the presence of Na+, conducts Ca2+ and Mg2+, but not Fe2+, impermeable to protons; inwardly rectifying Wild type TRPML3: γ = 59 pS at negative holding potentials with monovalent cations as charge carrier; conducts Na+ > K+ > Cs+ and Ca2+ (PCa/PK ∼ = 350), slowly inactivates in the continued presence of Na+ within the extracellular (extracytosolic) solution; outwardly rectifying
Comments	TRPML1 current is potentiated by acidic pH and sphingosine [http://www.ncbi.nlm.nih.gov/pubmed/22415822?dopt=AbstractPlus].	–	Current is activated by Na+‐free extracellular (extracytosolic) solution, and is inhibited by extracellular acidification (equivalent to intra‐lysosomal acidification). Channel blockers include the ML‐SI series of compounds (e.g. ML‐SI1; concentration range 5x10‐5 M; ‐120mV) [http://www.ncbi.nlm.nih.gov/pubmed/26027738?dopt=AbstractPlus].